Biologic switching in allergic bronchopulmonary aspergillosis: a scoping review of published clinical experience
Qiurong Hu, Xuanyu Pan, Ruchong Chen, Ganlu Li, Yixuan Li, Yu Zheng, Ziyang Zhong, Xinyi Zhang, Yuhang Chen, Jiazhen Ye, Jielin Duan, Jing Li · 2026
Read Biologic switching in allergic bronchopulmonary aspergillosis: a scoping review of published clinical experience by Qiurong Hu, Xuanyu Pan, Ruchong Chen, Ganlu Li, Yixuan Li, Yu Zheng, Ziyang Zhong, Xinyi Zhang, Yuhang Chen, Jiazhen Ye, Jielin Duan, Jing Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13266768.txt.
Description
Qiurong Hu and colleagues review in 2026 what happens when patients with allergic bronchopulmonary aspergillosis switch from one biologic drug to another. The lung condition involves strong type 2 inflammation, and targeted antibody drugs are used off-label when standard care falls short. Responses vary, so clinicians often try a second agent.
Across 31 publications, the team found 73 patients and 108 switches. Omalizumab was the most common first drug, and many patients moved next to drugs blocking interleukin-5 pathways, then later to dupilumab. Poor response and side effects drove most changes, and improvement was often reported afterward. Still, published reports are mostly single cases, so best ordering remains unknown.
Catalog record
| CREATOR | Qiurong Hu, Xuanyu Pan, Ruchong Chen, Ganlu Li, Yixuan Li, Yu Zheng, Ziyang Zhong, Xinyi Zhang, Yuhang Chen, Jiazhen Ye, Jielin Duan, Jing Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |